Clinical Trial NCT01504854
The number of Americans with Alzheimer's disease and other dementias will grow as the U.S. population age 65 and older continues to increase. It is projected more than 3 million people aged 85 and older are likely to have Alzheimer's, when the first wave of baby boomers reach age 85 in the year 2031 (Alzheimer's Association, 2015). By 2025, the number of people age 65 and older with Alzheimer's disease is estimated to reach 7.1 million -- a 40% increase from the 5 million who are age 65 and older currently affected (Alzheimer's Association, 2015). Alzheimer's disease is the most common type of dementia and is projected to be one of the most prevalent illnesses with our older adult population in the future. Alzheimer's disease remains 100% fatal and there is no cure for the disease; however, there are medications that are believed to be able to slow down the progression of the disease.
A study cosponsored by the National Institute of Aging (NIA) and the Alzheimer's Disease Cooperative Study (Clinical Trial Identifier NCT01504854; ClinicalTrials.gov, 2015) is investigating the effects of resveratrol, a phytoalexin that is a derivative from grapes and other food products that has an antioxidant property and potential chemopreventive...
One hundred and twenty participants with mild to moderate Alzheimer's disease (as determined by their scores on the Mini Mental Status Examination [MMSE]) will be randomly assigned to either a treatment (n = 60) or placebo control condition (n = 60). Resevertol treatment will start with 500 mg daily and increase in 13-week intervals to a maximum of 1 gm a day twice-daily; placebo treatment will be administered on the same schedule. Treatment duration is expected to be 52 weeks. The outcome measures for the study are various biomarker analysis of cerebrospinal fluid at baseline and again at week 52 of the study as well as changes in cognitive status as determined by changes in the MMSE and in the Clinical Dementia Rating Scale (CDR-SOB).
The participants will also receive MRI scanning at week 13 and again at week 52 and physical examination, neurological examination, and standard laboratory testing in order to monitor their progress in any physical complications of the treatment every six…
